Aura's Phase 1 trial shows promising results for bel-sar in bladder cancer. Four of five patients with low-grade disease had complete response post-treatment. The treatment induced rapid tumor response with immune effects in seven days. Bel-sar was well-tolerated; no serious adverse events reported in the study. AURA stock rose 18.85% following the positive trial data announcement.
Aura's bel-sar showed 80% tumor control in early-stage choroidal melanoma patients. 90% of patients preserved visual acuity post-treatment, exceeding standard care effects. No serious adverse events linked to bel-sar; safety profile is favorable. FDA agreed on Phase 3 trial design, strengthening bel-sar's development pathway. Aura stock rose 6.39% following positive Phase 2 results.
